In the latest trading session, Novo Nordisk (NVO) closed at $83.34, marking a -1.99% move from the previous day. This move lagged the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a ...

Novo Nordisk A/S’s blockbuster drug Wegovy was ... 17.5% reduction among people who got a standard dose — but was less than either the highest dose of Eli Lilly & Co.’s Zepbound or the ...

Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.

While Novo and Lilly both make attractive opportunities, recent news has me more bullish ... value is larger than Pfizer's, Moderna's, and J&J's combined! Moreover, Novo Nordisk is now the most ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

Novo Nordisk (NVO) closed at $85.73 in the latest trading session, marking a -1.88% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 1.07% for the day.

Danish pharmaceutical leader Novo Nordisk (NYSE: NVO ... it's important to zoom out and consider the bigger picture. In a study from 2021, patients taking semaglutide experienced an average ...